Xeris Biopharma Holdings (XERS) Net Margin (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Net Margin came in at 2.69% in Q1 2026, up 1802.0% YoY from 0.14% in Q1 2025, and down 79.19% on a QoQ basis from 12.91% in Q4 2025.
Xeris Biopharma Holdings (XERS) Net Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Net Margin data on file, last reported at 2.69% in Q1 2026.
- Quarterly Net Margin rose 1802.0% year-over-year to 2.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3.81% (up 2407.0% YoY) and the FY2025 annual result came in at 0.19%, up 2719.0% from the prior year.
- Net Margin eased to 2.69% in Q1 2026, from 12.91% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 12.91% in Q4 2025 to a low of 152.74% in Q1 2022.
- A 5-year average of 37.88% and a median of 30.16% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 20548 bps — and 2024, when it sank 377 bps.
- Tracing XERS's Net Margin over 5 years: stood at 39.01% in 2022, then rose by 23 bps to 30.16% in 2023, then jumped by 72 bps to 8.51% in 2024, then jumped by 252 bps to 12.91% in 2025, then slumped by 79 bps to 2.69% in 2026.
- The last three Net Margin figures came in at 2.69% (Q1 2026), 12.91% (Q4 2025), and 0.83% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -13.91% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 9.28% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 42.51% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -3.16% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 15.06% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 3.95% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | -33.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.77% |
| Mar 31, 2026 | 2.69% |
| Dec 31, 2025 | 12.91% |
| Sep 30, 2025 | 0.83% |
| Jun 30, 2025 | -2.70% |
| Mar 31, 2025 | -15.34% |
| Dec 31, 2024 | -8.51% |
| Sep 30, 2024 | -29.00% |
| Jun 30, 2024 | -31.22% |
| Mar 31, 2024 | -46.71% |
| Dec 31, 2023 | -30.16% |
| Sep 30, 2023 | -25.23% |
| Jun 30, 2023 | -52.20% |
| Mar 31, 2023 | -50.71% |
| Dec 31, 2022 | -39.01% |
| Sep 30, 2022 | -73.44% |
| Jun 30, 2022 | -103.47% |
| Mar 31, 2022 | -152.74% |
| Dec 31, 2021 | -237.02% |
| Sep 30, 2021 | -235.16% |